UBS Group
LGND icon

UBS Group’s Ligand Pharmaceuticals LGND Stock Holding History

UBS Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-122,309
Closed -$11.6M – 9616
2021
Q1 		$11.6M Buy
122,309
+68,769
+128% +$6.5M ﹤0.01% 1823
2020
Q4 		$3.32M Buy
+53,540
New +$3.05M ﹤0.01% 2886

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's LGND Position: Q2 2026 in Review

UBS Group increased its Ligand Pharmaceuticals (LGND) stake by 19% in Q2 2026, buying an estimated $4.73M and bringing the position to 124,674 shares worth $39.4M. The position accounts for 0.01% of the portfolio, ranked #1986.

UBS Group first reported a position in LGND in Q4 2014 and has held it in 47 quarters since. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • UBS Group held 124,674 shares of Ligand Pharmaceuticals worth $39.4M as of Q2 2026.
  • UBS Group bought 20,094 Ligand Pharmaceuticals shares in Q2 2026, an estimated $4.73M.
  • Ligand Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q2 2026, its #1986 holding.
  • UBS Group first reported a position in Ligand Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.